Scene And Heard At BIO – From The IN VIVO Blog
This article was originally published in The Pink Sheet Daily
Vaccine applications to FDA are booming; Vertex outgoing CEO Josh Boger on the vision of George Merck; Merck-Serono portfolio guru Vince Aurentz; a review of meeting swag, and more from Day 3 in Atlanta.
You may also be interested in...
Bayer pursued a “surreptitious” plan to supplant the cancer drug at the heart of a 15-year-old collaboration, according to a harshly-worded lawsuit.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.